您当前所在的位置:首页 > 产品中心 > 产品信息
Calcium Acetate_分子结构_CAS_62-54-4)
点击图片或这里关闭

Calcium Acetate

产品号 DB00258 公司名称 DrugBank
CAS号 62-54-4 公司网站 http://www.ualberta.ca/
分子式 C4H6CaO4 电 话 (780) 492-3111
分子量 158.16604 传 真
纯 度 电子邮件 david.wishart@ualberta.ca
保 存 Chembase数据库ID: 143

产品价格信息

请登录

产品别名

标题
Calcium Acetate
IUPAC标准名
calcium diacetate
IUPAC传统名
calcium(2+) bis(acetate ion)
商标名
Calac
Sorbo-calcian
Niacet calcium acetate tech
PhosLo
PhosLo Gelcaps
Sorbo-calcion
Teltozan
别名
Gray acetate of lime
Calcium acetate hydrate
Grey acetate
Acetic acid, calcium salt
Brown acetate
Brown acetate of lime
Calcium acetate monohydrate
Gray acetate
Procalamine
Vinegar salts
Calcium diacetate
Lime acetate
Lime pyrolignite
Pyrolignite of lime

产品登记号

PubChem CID 6116
PubChem SID 46507985
CAS号 62-54-4

产品性质

产品详细信息

详细说明 (English)
Item Information
Drug Groups approved
Description The chemical compound calcium acetate is the calcium salt of acetic acid. An older name is acetate of lime. The anhydrous form is very hygroscopic, therefore the monohydrate is the common form. [Wikipedia]
Indication Calcium acetate is one of a number of calcium salts used to treat hyperphosphatemia (too much phosphate in the blood) in patients with kidney disease.
Pharmacology Patients with advanced renal insufficiency (creatinine clearance less than 30 ml/min) exhibit phosphate retention and some degree of hyperphosphatemia. The retention of phosphate plays a pivotal role in causing secondary hyperparathyroidism associated with osteodystrophy, and soft-tissue calcification. The mechanism by which phosphate retention leads to hyperparathyroidism is not clearly delineated. Therapeutic efforts directed toward the control of hyperphosphatemia include reduction in the dietary intake of phosphate, inhibition of absorption of phosphate in the intestine with phosphate binders, and removal of phosphate from the body by more efficient methods of dialysis. The rate of removal of phosphate by dietary manipulation or by dialysis is insufficient. Dialysis patients absorb 40% to 80% of dietary phosphorus. Therefore, the fraction of dietary phosphate absorbed from the diet needs to be reduced by using phosphate binders in most renal failure patients on maintenance dialysis. Calcium acetate when taken with meals combines with dietary phosphate to form insoluble calcium phosphate which is excreted in the feces. Maintenance of serum phosphorus below 6.0 mg/dl is generally considered as a clinically acceptable outcome of treatment with phosphate binders. Calcium acetate is highly soluble at neutral pH, making the calcium readily available for binding to phosphate in the proximal small intestine.
Toxicity Oral, rat: LD50 = 4280 mg/kg. Symptoms of overdose include mild hypercalcemia (constipation; loss of appetite; nausea and vomiting), and severe hypercalcemia (confusion; full or partial loss of consciousness; incoherent speech).
Affected Organisms
Humans and other mammals
Absorption 40% is absorbed in the fasting state and approximately 30% is absorbed in the nonfasting state following oral administration.
Elimination Calcium acetate when taken with meals, combines with dietary phosphate to form insoluble calcium phosphate which is excreted in the feces.
External Links
Wikipedia
Drugs.com

参考文献